相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update
Arrigo F. G. Cicero et al.
MEDICINA-LITHUANIA (2021)
The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
Daisuke Okui et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia
Satoru Kuriyama
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study
Tatsuo Hosoya et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study
Tatsuo Hosoya et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)
Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout
Tatsuo Hosoya et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)
A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout
Tatsuo Hosoya et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)
Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study
Tatsuo Hosoya et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)
Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity
Junichiro Uda et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor
Tetsuya Taniguchi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Recent updates on worldwide gout epidemiology
Camilla Mattiuzzi et al.
CLINICAL RHEUMATOLOGY (2019)
Electrochemical analysis of uric acid excretion to the intestinal lumen: Effect of serum uric acid-lowering drugs and 5/6 nephrectomy on intestinal uric acid levels
Kyoko Fujita et al.
PLOS ONE (2019)
International position paper on the appropriate use of uricosurics with the introduction of lesinurad
Tim L. Jansen et al.
CLINICAL RHEUMATOLOGY (2018)
Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Jie-Ying Wu et al.
PHARMACOTHERAPY (2018)
Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations
Hiroshi Miyata et al.
Frontiers in Pharmacology (2017)
Lesinurad: what the nephrologist should know
Maria Dolores Sanchez-Nino et al.
CLINICAL KIDNEY JOURNAL (2017)
Definition of hyperuricemia and gouty conditions
Thomas Bardin et al.
CURRENT OPINION IN RHEUMATOLOGY (2014)
Extra-Renal Elimination of Uric Acid via Intestinal Efflux Transporter BCRP/ABCG2
Atsushi Hosomi et al.
PLOS ONE (2012)
Decreased extra-renal urate excretion is a common cause of hyperuricemia
Kimiyoshi Ichida et al.
NATURE COMMUNICATIONS (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Common Defects of ABCG2, a High-Capacity Urate Exporter, Cause Gout: A Function-Based Genetic Analysis in a Japanese Population
Hirotaka Matsuo et al.
SCIENCE TRANSLATIONAL MEDICINE (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
A benefit-risk assessment of benzbromarone in the treatment of gout - Was its withdrawal from the market in the best interest of patients?
Ming-Han H. Lee et al.
DRUG SAFETY (2008)
Mechanisms of benzarone and benzbromarone-induced hepatic toxicity
P Kaufmann et al.
HEPATOLOGY (2005)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Urate transport via human PAH transporter hOAT1 and its gene structure
K Ichida et al.
KIDNEY INTERNATIONAL (2003)
分享论文
